Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

X41226e40.d143.43b1.ac92.023809990077

— · cohortA1

f49dc2b2-06bc-54a5-b0fd-45525e88b07f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA1
subtype
cohortA1
age_years
67

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • TNFA_SIGNALING_VIA_NFKB+0.580
  • ALLOGRAFT_REJECTION+0.540
  • INFLAMMATORY_RESPONSE+0.520
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INTERFERON_GAMMA_RESPONSE+0.480
  • HYPOXIA+0.460
  • ANGIOGENESIS+0.400
  • INTERFERON_ALPHA_RESPONSE+0.380
  • MYOGENESIS+0.380

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.440
  • MYC_TARGETS_V1-0.430
  • PROTEIN_SECRETION-0.430
  • DNA_REPAIR-0.360
  • E2F_TARGETS-0.350
  • PEROXISOME-0.330
  • ADIPOGENESIS-0.240
  • FATTY_ACID_METABOLISM-0.240
  • G2M_CHECKPOINT-0.220
  • BILE_ACID_METABOLISM-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_PJPGVD62
brain-umap@2
Ependymoma NOS—0.944
2BS_PJPGVD62
medullo-epn-umap@date-based
EPNEPN Tumor0.926
3SRR26320074
bladder-landscape@3
——0.920
420120155.TNBC
breast-umap@18
—D0.911
5TCGA-77-8131-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.910
6SJEPD001518_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.909
7s_150324_1a
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.907
8SJEPD038_D.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.903
9SJEPD001506_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.903
10MNG133
mng-umap@100
——0.901

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.580Inavolisib— uncovered
ALLOGRAFT_REJECTION0.540Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.520Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.480Idelalisib— uncovered
HYPOXIA0.460Idelalisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.380Inavolisib— uncovered
MYOGENESIS0.380Inavolisib— uncovered
COAGULATION0.360Binimetinib— uncovered
COMPLEMENT0.360Inavolisib— uncovered
HEDGEHOG_SIGNALING0.310Inavolisib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
APICAL_JUNCTION0.290Inavolisib— uncovered
APICAL_SURFACE0.260Temsirolimus— uncovered
APOPTOSIS0.260Idelalisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
KRAS_SIGNALING_DN0.220Remibrutinib— uncovered